Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG + Pembrolizumab in Advanced SCCHN
NCT03246685Phase 2Terminated
- Sponsor
- HiberCell
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of odetiglucan in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by HiberCell. Primary endpoint: Overall Response Rate at 18 months. Started Nov 2017; status: terminated.
02
Drugs
odetiglucan
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03246685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03246685.